Compare Stocks: PHAR, GMTX, ZLAB, and SLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$60.48 -2.5%	$73.26	$1.16 ▼ $14.10	$2.62B	-0.12	189,291 shs	657,218 shs
PHAR Pharming Group	$9.44 -1.8%	$10.93	$9.32 ▼ $21.34	$680.18M	-0.05	33,057 shs	28,940 shs
SLS SELLAS Life Sciences Group	$12.41 +4.0%	$12.50	$1.39 ▼ $15.88	$2.41B	2.56	5.21 million shs	6.37 million shs
ZLAB Zai Lab	$23.10 -6.1%	$25.25	$15.96 ▼ $30.18	$2.80B	0.73	804,684 shs	778,448 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	-2.55%	-4.50%	-13.67%	-19.37%	-13.48%
PHAR Pharming Group	-1.77%	-2.48%	-15.79%	-29.55%	-35.39%
SLS SELLAS Life Sciences Group	+4.02%	+9.44%	+7.45%	-2.97%	+520.50%
ZLAB Zai Lab	-6.06%	-9.70%	-4.31%	+13.01%	-26.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$60.48 -2.5%	$73.26	$1.16 ▼ $14.10	$2.62B	-0.12	189,291 shs	657,218 shs
PHAR Pharming Group	$9.44 -1.8%	$10.93	$9.32 ▼ $21.34	$680.18M	-0.05	33,057 shs	28,940 shs
SLS SELLAS Life Sciences Group	$12.41 +4.0%	$12.50	$1.39 ▼ $15.88	$2.41B	2.56	5.21 million shs	6.37 million shs
ZLAB Zai Lab	$23.10 -6.1%	$25.25	$15.96 ▼ $30.18	$2.80B	0.73	804,684 shs	778,448 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	-2.55%	-4.50%	-13.67%	-19.37%	-13.48%
PHAR Pharming Group	-1.77%	-2.48%	-15.79%	-29.55%	-35.39%
SLS SELLAS Life Sciences Group	+4.02%	+9.44%	+7.45%	-2.97%	+520.50%
ZLAB Zai Lab	-6.06%	-9.70%	-4.31%	+13.01%	-26.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
PHAR Pharming Group	2.20	Hold	$38.67	309.60% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-19.42% Downside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	61.26% Upside

Current Analyst Ratings Breakdown

Latest PHAR, GMTX, ZLAB, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/23/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$38.00
9/22/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$37.00
9/14/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$37.00
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
8/7/2026	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$44.00 ➝ $45.00
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
7/29/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
PHAR Pharming Group	$376.13M	1.78	$0.20 per share	47.92	$3.95 per share	2.39
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A
ZLAB Zai Lab	$460.16M	5.71	N/A	N/A	$6.39 per share	3.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
PHAR Pharming Group	$2.85M	$0.12	78.67	34.96	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest PHAR, GMTX, ZLAB, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	SLS SELLAS Life Sciences Group	-$0.05	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	PHAR Pharming Group	$0.12	N/A	N/A	N/A	$103.54 million	N/A
11/5/2026	Q3 2026	ZLAB Zai Lab	-$0.5642	N/A	N/A	N/A	$108.84 million	N/A
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMTX Gemini Therapeutics	N/A	71.49	71.49
PHAR Pharming Group	0.34	3.01	2.31
SLS SELLAS Life Sciences Group	N/A	18.83	18.83
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMTX Gemini Therapeutics	75.42%
PHAR Pharming Group	0.03%
SLS SELLAS Life Sciences Group	17.38%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
GMTX Gemini Therapeutics	12.90%
PHAR Pharming Group	2.07%
SLS SELLAS Life Sciences Group	1.30%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable
SLS SELLAS Life Sciences Group	13	201.95 million	199.32 million	Not Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

PHAR, GMTX, ZLAB, and SLS Headlines

Recent News About These Companies

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

1 hour ago | marketscreener.comM

Zai Lab (NASDAQ:ZLAB) Stock Price Down 6.3% - Should You Sell?

October 13 at 1:01 PM | marketbeat.com

Zai Lab stock closed at USD 25.58 before ESMO data

October 7, 2026 | ad-hoc-news.deA

Critical Comparison: Zai Lab (NASDAQ:ZLAB) vs. Anixa Biosciences (NASDAQ:ANIX)

October 7, 2026 | americanbankingnews.com

Zai Lab stock faces a key ESMO test after Cantor target call

October 7, 2026 | ad-hoc-news.deA

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's Why

October 6, 2026 | marketbeat.com

Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?

October 4, 2026 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6% - Here's Why

October 2, 2026 | marketbeat.com

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

September 29, 2026 | marketscreener.comM

Zai Lab (NASDAQ:ZLAB) Stock Jumps 3.8% - What's Next?

September 28, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Raised to "Hold" at Wall Street Zen

September 26, 2026 | marketbeat.com

Zai Lab Ltd (ZLAB)

September 24, 2026 | in.investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2026 | marketbeat.com

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAR, GMTX, ZLAB, and SLS Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

$60.48 -1.58 (-2.55%)

As of 10/12/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Pharming Group NASDAQ:PHAR

$9.44 -0.17 (-1.77%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$9.69 +0.25 (+2.65%)

As of 07:40 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

SELLAS Life Sciences Group NASDAQ:SLS

$12.41 +0.48 (+4.02%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$12.30 -0.11 (-0.85%)

As of 09:01 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Zai Lab NASDAQ:ZLAB

$23.10 -1.49 (-6.06%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$22.31 -0.79 (-3.43%)

As of 08:57 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, GMTX, ZLAB, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, GMTX, ZLAB, and SLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, GMTX, ZLAB, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, GMTX, ZLAB, and SLS Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

Pharming Group NASDAQ:PHAR

SELLAS Life Sciences Group NASDAQ:SLS

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, GMTX, ZLAB, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, GMTX, ZLAB, and SLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, GMTX, ZLAB, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, GMTX, ZLAB, and SLS Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

Pharming Group NASDAQ:PHAR

SELLAS Life Sciences Group NASDAQ:SLS

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools